Last reviewed · How we verify
Low intensity therapies
Low intensity therapies refer to reduced-dose or less aggressive treatment regimens designed to maintain efficacy while minimizing toxicity in cancer patients.
Low intensity therapies refer to reduced-dose or less aggressive treatment regimens designed to maintain efficacy while minimizing toxicity in cancer patients. Used for Cancer treatment in elderly or frail patients.
At a glance
| Generic name | Low intensity therapies |
|---|---|
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Low intensity therapies typically involve dose reductions, extended dosing intervals, or simplified treatment schedules compared to standard protocols. These approaches are particularly relevant in elderly patients, those with comorbidities, or patients with poor performance status, aiming to improve tolerability and quality of life while preserving therapeutic benefit.
Approved indications
- Cancer treatment in elderly or frail patients
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- New York Better Breathing Study (NA)
- Exercise and Mindfulness in Patients With Non-specific Chronic Low Back Pain: The BACKFIT Project (NA)
- Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study (NA)
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
- Variable Intensive Early Walking Post-Stroke - 2 (VIEWS-2) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: